Psychopharmacological Agents During Pregnancy and Nursing

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F22%3A43920379" target="_blank" >RIV/00023752:_____/22:43920379 - isvavai.cz</a>

Výsledek na webu

<a href="https://link.springer.com/referenceworkentry/10.1007/978-3-030-62059-2_268" target="_blank" >https://link.springer.com/referenceworkentry/10.1007/978-3-030-62059-2_268</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-3-319-56015-1_268-1" target="_blank" >10.1007/978-3-319-56015-1_268-1</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Psychopharmacological Agents During Pregnancy and Nursing

Popis výsledku v původním jazyce

Decision-making about pharmacotherapy of mental disorders during pregnancy and lactation is a source of uncertainty in clinical practice. Potentially deleterious effects of drugs on the fetus and the infant are much feared; but at the same time, negative impact of untreated mental disorder have to be taken into account. Discontinuation of long-term medication increases greatly the risk of a relapse, may worsen the course of illness and result in poor overall outcome. Drug pharmacokinetics is markedly changed throughout the pregnancy and postpartum; thus, the dosage has to be adjusted appropriately. It should be emphasized that mental disorders alone have been associated with numerous pre-, peri- and postnatal complications and adverse effects on the fetus and the infant. Therefore, not all negative outcomes can be attributed to the medication. All psychotropic drugs cross placental barrier and pass into the maternal milk. The risk associated with drug treatment in pregnancy depends primarily on the period of exposure, gestational age. Teratogenic potential is greatest during the first trimester, neurobehavioral effects during the exposure in the last trimester, and withdrawal and intoxication with administration prior to the delivery. The chapter reviews available data on the risks and safety of antipsychotics, antidepressants, mood stabilizers, anxiolytics, hypnotics and other psychopharmacological agents in pregnancy and nursing.

Název v anglickém jazyce

Psychopharmacological Agents During Pregnancy and Nursing

Popis výsledku anglicky

Decision-making about pharmacotherapy of mental disorders during pregnancy and lactation is a source of uncertainty in clinical practice. Potentially deleterious effects of drugs on the fetus and the infant are much feared; but at the same time, negative impact of untreated mental disorder have to be taken into account. Discontinuation of long-term medication increases greatly the risk of a relapse, may worsen the course of illness and result in poor overall outcome. Drug pharmacokinetics is markedly changed throughout the pregnancy and postpartum; thus, the dosage has to be adjusted appropriately. It should be emphasized that mental disorders alone have been associated with numerous pre-, peri- and postnatal complications and adverse effects on the fetus and the infant. Therefore, not all negative outcomes can be attributed to the medication. All psychotropic drugs cross placental barrier and pass into the maternal milk. The risk associated with drug treatment in pregnancy depends primarily on the period of exposure, gestational age. Teratogenic potential is greatest during the first trimester, neurobehavioral effects during the exposure in the last trimester, and withdrawal and intoxication with administration prior to the delivery. The chapter reviews available data on the risks and safety of antipsychotics, antidepressants, mood stabilizers, anxiolytics, hypnotics and other psychopharmacological agents in pregnancy and nursing.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30215 - Psychiatry

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

NeuroPsychopharmacotherapy

ISBN

978-3-030-62058-5

Počet stran výsledku

27

Strana od-do

4355-4381

Počet stran knihy

4784

Název nakladatele

Springer

Místo vydání

Berlin

Kód UT WoS kapitoly

—